S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show

bluebird bio: How to play LEAPS options for growth and income

→ My biggest AI fear (From Paradigm Press) (Ad)
Trade Alerts bluebird bio

Key Points

  • bluebird bio is a major beneficiary of gene therapy headlines as it has 3 FDA approval therapies.
  • bluebird was a $158 stock in 2019, which has fallen as low as 87 cents in 2024.
  • OTM LEAPS calls can be held while selling OTM front-month calls for income.
  • 5 stocks we like better than bluebird bio

Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT from CRISPR Therapeutics AG NASDAQ: CRSP and partner Vertex Pharmaceuticals Inc. NASDAQ: VRTX. CASGEVY made global headlines when it received FDA approval on December 8, 2023.However, on the same day, the FDA also approved LYFGENIA (lovotibeglogene autotemcel), which is another gene therapy treatment for SCD by bluebird bio NASDAQ: BLUE. At the same time, CRISPR Therapeutics is getting the bulk of the attention, while Little Bluebird Bio benefits from the secular tailwinds forming with gene therapy. bluebird has 3 FDA approved gene therapies:

LYFGENIA (lovotibeglogene autotemcel) was FDA approved on the same day as gene-editing therapy CASGEVY on December 8, 2023, for the treatment of sickle cell disease (SCD). LYFGENIA is the longest-studied approved gene therapy for SCD. It's designed to allow the production of anti-sickling hemoglobin to decrease vaso-occlusive events.

ZYNTEGLO (betibeglogene autotemcel) is a gene therapy treatment for beta-thalassemia characterized by the inefficient production of healthy red blood cells. Patients receive functional copies of the beta-globin gene. Studies have shown that 89% of patients achieved transfusion independence.

SKYSONA (elivaldogene autotemcel) is a gene therapy treatment for early active cerebral adrenoleukodystrophy (CALD). It’s the first and only gene therapy proven to slow the progression of neurologic dysfunction in boys with early and active CALD.


How to play BLUE with LEAPS options for growth and income

BLUE is attractive to speculators because its frankly a cheap stock. Much cheaper than CRSP, with large relative upside potential. We can look to play the stock options using Long-term Equity AnticiPation Securities (LEAPS) or LEAP calls, which are relatively cheap. Fundamentally, BLUE is a solid speculation that will benefit from the continued headlines for gene therapies, including gene editing. It's also the rare company with 3 FDA approvals for gene therapies. It's LYSENIA is a $3.3 million treatment, but it's making progress with reimbursement from insurers, especially as CASGEVY makes ground on it.

bluebird stock chart

 

BLUE weekly cup breakout into gap zone

Since we’re looking at LEAPS, we will use a larger weekly time frame to see the big picture of the price landscape for our technical analysis. Hard to believe, but BLUE was trading at a high of $152.88 in March 2018. BLUE fell to a low of 87 cents in February 2023, forming a rounding bottom. The weekly market structure low (MSL) buy triggers above $1.47. The daily MSL triggered above $1.13. The weekly cup lip line formed in January 2024 at $1.53, making it the ley line in the sand resistance, gap zone reentry and breakout level. The weekly relative strength index (RSI) is rising through the 40-band. Pullback support levels at $1.40, $1.26, $1.13 and 97 cents.

bluebird bio call sheet

 

Long BLUE $2 LEAPS calls

Since we are giving BLUE time to break out and accelerate to the upside, we take the BLUE $2 LEAPS expiring January 17, 2025, or in 326 days for 60 cents. This is an out-of-the-money (OTM) directional options trade. Analyzing the option Greeks tells us that the 64.5 Delta implies the call options will gain 64.5 cents for each $1 move in the underlying shares.

The Theta implies the option will lose .0011 cents in value per day from time decay until expiration. The breakeven cost on the option is $2.55 on expiration. If BLUE surges ahead of time, the Delta will spike at the rate of the Gamma, and the option will be worth more. The $2.26 is the gap fill level, with the next gap fill at $3.94, and a swing high of $5.53 was made on the FDA approval date of December 8, 2023. That would be the upside target.

Sell OTM calls for income.

If BLUE rises above $2.00 and gets in the money (ITM), we can start generating income using the long call diagonal debit spread (LCDDS) strategy. Since we already own the LEAPS call option, we can sell OTM calls against the long LEAPS call position.

bluebird stock calls

Even without going ITM, ee can sell the BLUE $2 Calls expiring April 19, 2024, in 53 days for 15 cents per contract. The $2 LEAPS cost us 60 cents. The 15-cent premium represents a 25% yield for holding the LEAP calls for 53 days. If BLUE spikes to $2.00, then our LEAPS calls would also rise in value too, with the potential to be assigned.

If you don't want to risk assignment, you can sell deeper OTM calls, like the $2.50 April calls, which will provide lower premiums. As BLUE shares rise, you can select higher strike prices. The premiums also buffer any downside moves.

 

→ My biggest AI fear (From Paradigm Press) (Ad)

Should you invest $1,000 in bluebird bio right now?

Before you consider bluebird bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bluebird bio wasn't on the list.

While bluebird bio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
bluebird bio (BLUE)
2.741 of 5 stars
$1.10-5.2%N/A-1.49Hold$5.87
Vertex Pharmaceuticals (VRTX)
4.3298 of 5 stars
$396.55-0.9%N/A28.55Hold$420.33
CRISPR Therapeutics (CRSP)
1.3604 of 5 stars
$60.67-3.6%N/A-30.95Hold$74.75
Compare These Stocks  Add These Stocks to My Watchlist 

Jea Yu

About Jea Yu

  • JeaYu21@gmail.com

Contributing Author

Trading Strategies

Experience

Jea Yu has been a contributing writer for MarketBeat since 2018.

Areas of Expertise

Equities, options, ETFs and futures; fundamental, qualitative, quantitative and technical analysis and pattern identification; active and swing trading; trading systems and methodology development

Education

Bachelor of Arts, University of Maryland, College Park

Past Experience

U.S. equity markets trader, writer and analyst for over 25 years. Published four books by publishers McGraw-Hill, John Wiley & Sons, Marketplace Books and Bloomberg Press. Speaker at various expos and seminars and has been quoted and featured in USA Today, The Wall Street Journal, Traders Magazine, The Financial Times and various trade publications, including Stocks & Commodities, Active Trader and Online Investor.


Featured Articles and Offers

Search Headlines: